Efficacy of postoperative adjuvant transfusion of cytokine-induced killer cells combined with chemotherapy in patients with colorectal cancer

Zhu, Yuan Xiao; Zhang, Haibo; Li, Yong; Bai, Jie; Liu, Lirong; Liu, Yihong; Qu, Ying; Qu, Xin

doi:10.1007/s00262-013-1465-z

Cited by 38 publications

(40 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of these, 1 patient with lymphoma experienced complete remission, while 6 patients exhibited disease progression, and 3 did not experience any alteration on their condition (5,11). Other clinical studies subsequently confirmed the safety and benefits of CIK cell-based therapy, alongside initial clinical activity (12,13).…”

Section: Introductionmentioning

confidence: 67%

“…Furthermore, CIK cells are able to regulate cellular immune functions in patients with cancer (35,36). The application of CIK cells as adoptive immunotherapy is important in the treatment of cancer, since several clinical studies have confirmed the safety of CIK therapy for patients (12,13). Numerous clinical studies have been recently performed, whereby adjuvant infusions of CIK cells following surgical resection demonstrated a significant increase in survival time (43,44).…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have reported that a combination of chemotherapy, surgical operation and radiotherapy alongside CIK cell therapy may control local tumors while promoting antitumor activity and immune responses (12,16 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of cytokine-induced killer cells on immune function in patients with lung cancer

Pan

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Cytokine-induced killer (CIK) cells have been used as adoptive immunotherapy in cancer. The present study evaluated the effect of CIK cells on immune function in patients with lung cancer. Patients were divided into three groups, according to the treatment received prior to CIK cell treatment: CIK group (no prior treatment), Che-Sur group (prior chemotherapy and surgery) and Che-Rad group (prior chemotherapy and radiotherapy). Following treatment, the average percentage of cluster of differentiation (CD)3 + CD4 + , CD3 + , natural killer (NK) and NKT cells in peripheral blood was significantly higher than that prior to CIK treatment in the Che-Sur and CIK groups, and the levels of interferon-γ in serum were significantly higher than those prior to CIK treatment in the Che-Sur and CIK groups. On the contrary, the levels of interleukin-10 had decreased in these groups following CIK treatment. Subsequently, patients were divided into three groups according to the percentage of CD3 + CD56 + CIK cells that were administered to the patients. The number of NK and NKT cells increased with increasing number of CD3 + CD56 + cells. The patients in the CIK and Che-Sur groups were the most benefited ones following CIK treatment, contrarily to those in the Che-Rad group, since the increase in the number of CD3 + CD56 + CIK cells in the aforementioned patients enhanced the number of NK cells, which exhibit antitumor activity.

show abstract

Section: Introductionmentioning

confidence: 67%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of cytokine-induced killer cells on immune function in patients with lung cancer

Pan

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Adjuvant transfusion of CIK cells prolongs DFS in patients with colorectal cancer from 29.35 ± 6.39 % in control without CIK cells to 59.65 ± 24.80 % with CIK transfusion, and no immediate adverse reactions to the CIK cell transfusions (Zhu et al, 2013). DC/CIK therapy also reduced the risk of postoperative disease progression with an increased OS in gastric and colorectal cancer patients (Gao et al, 2014).…”

Section: Clinical Trialsmentioning

confidence: 93%

Cytokine induced killer cell immunotherapy in cancer treatment: from bench to bedside

Arafar¹

2014

Biomed Res Ther

View full text Add to dashboard Cite

Abstract-Cytokine-induced killer (CIK) cells are T effector cells generated by monocytes cultured and stimulated by cytokines. CIK cells were studied for more than 20 years ago. They can cause lysis of tumor cells that of both autologous and allogeneic origins, so that they were used in cancer treatment. This review aimed to summarize advancements of CIK cells and their current clinical applications in cancer treatment. In general, CIK cells were widely clinically used for recent 5 years. They gave promising results in hepatocellular carcinoma, lung cancer, breast cancer, renal cancer, and treatment. Looking into the future, CIK cell based immunotherapy will become an important tool in cancer treatment.

show abstract

“…In each cycle, the fresh cord blood was collected and cultured, and the derived CB-CIK cells were then administered. For patients who accepted CB-CIK transfusion combined with chemotherapy, the CB-CIK cells were infused at intervals of at least 1 day before or after chemotherapy [25]. However, the patients with various tumors had the different chemotherapy treatment protocols.…”

Section: Treatment Plan With Cb-cik Cellsmentioning

confidence: 99%

Efficacy and safety of cord blood–derived cytokine-induced killer cells in treatment of patients with malignancies

et al. 2015

View full text Add to dashboard Cite

Efficacy of postoperative adjuvant transfusion of cytokine-induced killer cells combined with chemotherapy in patients with colorectal cancer

Cited by 38 publications

References 26 publications

Effect of cytokine-induced killer cells on immune function in patients with lung cancer

Effect of cytokine-induced killer cells on immune function in patients with lung cancer

Cytokine induced killer cell immunotherapy in cancer treatment: from bench to bedside

Efficacy and safety of cord blood–derived cytokine-induced killer cells in treatment of patients with malignancies

Contact Info

Product

Resources

About